MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors Meeting Abstract
| Authors: | Lakhani, N. J.; Melisi, D.; Subbiah, V.; Ammakkanavar, N. R.; O'Reilly, E. M.; Cassier, P. A.; Wainberg, Z. A.; Duffy, A. G.; Patnaik, A.; Fujiwara, Y.; Oberstein, P. E.; Garcia-Carbonero, R.; Wright, J.; Lin, A. K.; Li, J.; Axelson, M. D.; Garrido-Laguna, I. |
| Abstract Title: | MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.TPS845 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting abstract: TPS845 -- Source: CINAHL Plus with Full Text |
